乙胺作为急性心力衰竭的宝贵补充剂?
1From the UPMC St. Margaret Family Medicine Residency Program, Pittsburgh, PA.
概括
对于急性不补偿性心力衰竭,请考虑将静脉注射乙胺添加到标准静脉注射循环利尿剂治疗中. 这种组合可能会改善住院患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性不补偿性心力衰竭 (ADHF) 是住院的主要原因.
- 尿剂耐药性是ADHF管理中的常见并发症.
- 循环利尿剂是ADHF的利尿症的基石.
研究的目的:
- 为了评估在ADHF患者的循环利尿剂中添加静脉注射乙胺的疗效.
- 评估对利尿和临床结果的影响.
主要方法:
- 住院ADHF患者的回顾性分析.
- 标准循环利尿剂治疗与添加静脉注射乙胺的治疗之间的比较.
- 分析尿液输出,自然化和停留时间.
主要成果:
- 接受阿西塔佐胺治疗的患者显示尿液输出增加.
- 与单独的循环利尿剂相比,添加乙醇胺改善了自然尿动.
- 没有观察到不良事件的显著增加.
结论:
- 静脉注射的乙醇胺可能是ADHF中循环利尿剂的有益补充剂.
- 这种组合可以克服利尿剂耐药性并增强脱血.
- 需要进一步的前性研究来证实这些发现.
相关概念视频
Heart Failure Drugs: Diuretics
367
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
367
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Heart Failure Drugs: Inotropic Agents
573
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
573
Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antihypertensive Drugs: Thiazide-Class Diuretics
611
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
611


